Evidence map›Paper›PMID 40148852›Full record

ArticleBMC neurology2025

Social Cognitive Treatment (T-ScEmo) for Various Neurological Patient Groups: Study Rationale and Protocol for a Randomized Control Trial (T-ScEmo4ALL).

A Heegers, S E Rakers, S van Twillert, V R M Moulaert, M M J Gerritsen, J van der Naalt, J M Spikman, H J Westerhof-Evers

Registry-linked trialAbstract readClinical Trial Protocol
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06330298 (Improving Social Cognition and Social Behaviour in Various Brain Disorders.), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06330298 naunknown statusnot on this map

Improving Social Cognition and Social Behaviour in Various Brain Disorders.

TypeinterventionalSponsorUniversity Medical Center GroningenRan2021 to 2025Enrolled84ConditionsStroke, Multiple Sclerosis, Brain TumorArmsTreatment social cognition and emotion regulation (T-ScEmo)
3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

A HeegersDepartment Clinical Neuropsychology, University of Groningen, University Medical Center, Hanzeplein 1, Groningen, GZ, 9713, the Netherlands. a.heegers@umcg.nl.
S E RakersDepartment Clinical Neuropsychology, University of Groningen, University Medical Center, Hanzeplein 1, Groningen, GZ, 9713, the Netherlands.
S van TwillertUMC Staff Policy and Management Support, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.
V R M MoulaertCenter for Rehabilitation, University of Groningen, University Medical Center, Groningen, the Netherlands.
M M J GerritsenDepartment of Medical Psychology, Deventer Hospital, Deventer, the Netherlands.
J van der NaaltDepartment of Neurology, University of Groningen, University Medical Center, Groningen, the Netherlands.
J M SpikmanDepartment Clinical Neuropsychology, University of Groningen, University Medical Center, Hanzeplein 1, Groningen, GZ, 9713, the Netherlands.
H J Westerhof-EversDepartment Clinical Neuropsychology, University of Groningen, University Medical Center, Hanzeplein 1, Groningen, GZ, 9713, the Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSocial cognitive impairments often occur in patients with various neurological disorders that involve brain damage, such as traumatic brain injury, stroke, brain tumours, and multiple sclerosis. Patients with social cognitive impairments experience difficulties in perceiving and understanding social information and show social inadequate behaviour. Recently, the first multi-faceted treatment, T-ScEmo (Treatment for Social Cognition and Emotion Regulation) has been developed and evaluated for patients with TBI. T-ScEmo showed to be effective in improving social cognitive functioning, participation, relationships, and quality of life. Up to now, no evidence-based treatment has been available for social cognitive impairments in neurological patients other than traumatic brain injury. Therefore, the main aims of the current study are to investigate the efficacy of T-ScEmo in various neurological patient groups such as stroke (including subarachnoid haemorrhage), brain tumours, and multiple sclerosis and to study factors that might influence this, potential, efficacy.

methodsIn this multi-centre, assessor-blind randomized controlled trial, 84 patients with mixed aetiology will be randomly divided over a treatment condition and a waiting list condition. Patients in treatment condition will follow twenty T-ScEmo sessions, of which five are online. Neuropsychological assessment and questionnaires directly after treatment (T1) and follow-up (T2, three to five months after treatment) will be compared to baseline assessment (T0). Ten TBI patients who receive T-ScEmo as regular rehabilitation care will be included as an extra control group. The main outcome measure will be the comparison of proxy rated behaviour between T0 and T2 on the Dysexecutive Questionnaire Social scales proxy version. Moreover, a compact barrier analysis is performed to facilitate the implementation of the treatment and to provide input for a process evaluation in the current study protocol. DISCUSSION: When T-ScEmo is proven effective based on the current study, this will be the first effectual evidence-based multi-faceted treatment for patients with social cognitive impairments caused by various neurological disorders. Implementation of this treatment is expected to contribute to better participation and better quality of life for patients and their significant others.

trial registrationThis study is prospectively registered in the database PaNaMa under number 202000479. Furthermore the study is registered in the database of clinicaltrials.gov (Study Details | Improving Social Cognition and Social Behaviour in Various Brain Disorders | ClinicalTrials.gov) under identifier NCT06330298.

Indexed as

Cognitive Behavioral TherapyCognitive DysfunctionNervous System DiseasesSocial CognitionAdultFemaleHumansMaleMiddle AgedMultiple SclerosisNeuropsychological TestsQuality of LifeRandomized Controlled Trials as TopicStrokeTreatment OutcomeYoung AdultBrain TumourMultiple SclerosisNeurological disordersSocial cognitionStrokeStudy ProtocolSubarachnoid HaemorrhageTraumatic Brain InjuryTreatmentT-ScEmo

Identifiers

PMID40148852
PMCPMC11948743

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.